Skip to main content

Table 1 Characteristics of the patients and clinical data depending on HAART use during ICU stay*

From: Should highly active antiretroviral therapy be prescribed in critically ill HIV-infected patients during the ICU stay? A retrospective cohort study

Characteristics and clinical data Total (n = 91) without HAART (n = 59) with HAART (n = 32) p
Characteristics     
Age (in years) 42 ± 10 42 ± 9 43 ± 11 0.98
Sex (M/F) 61/30 40/19 21/11 0.99
SAPS II on admission 47 ± 20 48 ± 21 46 ± 17 0.83
Glasgow score 12 ± 4 12 ± 5 13 ± 4 0.24
Main reasons for ICU admission     
Respiratory 46 (51) 28 (47) 18 (56) 0.51
Neurologic 25 (27) 16 (27) 9 (28) 0.99
Shock 10 (11) 6 (10) 4 (13) 0.99
Others 10 (11) 9 (15) 1 (3) 0.09
HIV infection     
Initial HIV diagnosis 17 (19) 16 (27) 1 (3) 0.004
Stage C 69 (76) 43 (73) 26 (81) 0.85
CD4 count at admission (cells/mm3) 112 [1–935] 100 [2–935] 161 [1–822] 0.68
Viral load at admission (log10) 3.38 ± 1.60 3.86 ± 1.51 2.63 ± 1.45 0.0005
AIDS related diagnosis at ICU admission 46 (51) 33 (56) 13 (41) 0.25
Opportunistic infections     
Pneumocystis jirovecii 12 10 2 0.2
Toxoplasmosis 7 5 2 0.99
Mycobacterial infections 7 4 3 0.69
Pneumonia 3 2 1 0.99
Others 5 3 2 0.99
Care in ICU     
Mechanical ventilation (MV) 45 (49) 29 (49) 16 (32) 0.87
Duration of ventilation (days) 5 ± 10 5 ± 11 5 ± 9 0.81
Renal replacement 7 (8) 3 (5) 4 (13) 0.33
Vasoactive drugs 22 (24) 15 (25) 7 (22) 0.99
Duration of vasoactive drugs (days) 1 ± 2 1 ± 2 1 ± 2 0.99
ICU length of stay (days) 8 ± 10 8 ± 11 8 ± 9 0.43
Death in ICU 17 (19) 12 (20) 5 (16) 0.78
  1. *Data are presented as No. (%) or mean ± SD, except for CD4 cell count which are expressed as median [range].